NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- UTIs therapeutics currently exhibits a proliferating pipeline with 40 drug candidates, according to P&S Market Research.
Urinary tract infection (UTI) refer to a common bacterial infection disease, that occurs in either a community or healthcare setting. Clinically, UTIs are categorized as uncomplicated and complicated. Uncomplicated UTIs typically occur in a healthy adult non-pregnant woman and have no structural or neurological urinary tract abnormalities; these infections are differentiated into cystitis and pyelonephritis.
Request for Sample Pages: https://www.psmarketresearch.com/market-analysis/utis-therapeutics-pipeline/report-sample
UTIs are caused by both gram-negative and gram-positive bacteria, as well as by certain fungi. Gram-negative rod Escherichia coli is the most common cause of UTIs in all settings and is transmitted by person-to-person direct contact and the fecal-oral route. The study analyzed that UTIs therapeutics pipeline comprises approximately 40 drug candidates in different stages of development.
According to the research findings, a majority of the drug candidates for the treatment of UTIs are being developed as small molecules. It has been observed that the drugs that are being developed as small molecules are easy to manufacture with high production rate.
Browse Detailed Report on "Urinary Tract Infections (UTIs) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" at: https://www.psmarketresearch.com/market-analysis/utis-therapeutics-pipeline
It has been observed that a majority of the companies in the UTIs therapeutic pipeline are developing drug candidates by using advanced technologies and these drug candidates have further shown positive efficacy in the clinical stage of development. For instance, MULTIPHORE Drug Design platform developed by Talon Pharmaceuticals Inc., specifies the complexity of the disease in nature. The above-mentioned technology is designed to identify the drug that interacts with multiple disease target through careful incorporation of multiple pharmacophores into a single molecule or through unique combination of different mechanisms of action implicated in the disease state.
The companies involved in the UTIs therapeutic pipeline are developing various drug candidates as combination therapies, that have several advantages such as, improved medication compliance by decreasing the pill burden of patients, increased efficacy, and reduced side effects and cost. For instance, C-Scape, a Phase I drug candidate by Achaogen Inc. is a combination of ceftibuten and clavulanate, that are small molecules obtained from the synthetic source. Both ceftibuten and clavulanate act by different mechanism of action but give synergistic effects. Ceftibuten acts as cell wall synthesis inhibitor and, clavulanate acts as beta-lactamase inhibitor.
Some of the key players involved in the development of UTIs therapeutics pipeline include Achaogen Inc., AmpliPhi Biosciences Corporation, and Iterum Therapeutics Limited.
UTIs Therapeutics Pipeline Analysis
- By Phase
- By Molecule Type
- By Route of Administration
- By Company
More Reports by P&S Market Research
mTOR Inhibitors Therapeutics - Pipeline Analysis 2017
According to the research findings, most of the drug candidates that act as mTOR inhibitors are being developed as small molecules, further supported by the fact that small molecules have several advantages such as it can be manufactured with production rate higher than any other molecule types.
https://www.psmarketresearch.com/market-analysis/mtor-inhibitors-therapeutics
Presbyopia Therapeutics - Pipeline Analysis 2018
Various pharmaceutical companies such as Novartis AG, Allergan Plc., Janssen Global Services LLC, and Acucela Inc. are engaged in the development drug candidates for the treatment of presbyopia.
https://www.psmarketresearch.com/market-analysis/presbyopia-therapeutics-pipeline-analysis
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook